• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi and APHRC sign MoU to forge strategic alliance to bridge research and capacity enhancement gaps

Home > News

DNDi and APHRC sign MoU to forge strategic alliance to bridge research and capacity enhancement gaps

Dr Joseph Gichuru, Deputy Executive Director and the Director of Operations, APHRC, and Prof. Samuel Kariuki, Continental Lead Africa and Eastern Africa Director, DNDi
Dr Joseph Gichuru, Deputy Executive Director and the Director of Operations, APHRC, and Prof. Samuel Kariuki, Continental Lead Africa and Eastern Africa Director, DNDi
27 Jan 2026

The Drugs for Neglected Diseases initiative (DNDi) and the African Population and Health Research Center (APHRC) have signed a memorandum of understanding (MoU) to promote joint research, foster innovation, and deliver evidence-based programmes, policy support, and capacity-building services to relevant stakeholders. Centring on engagement with academic institutions, policymakers, practitioners, and communities, this partnership is a commitment to transforming African-led research into impactful health policy and life-saving medical tools.

The MoU was signed by Prof. Samuel Kariuki, Continental Lead Africa and Eastern Africa Director, DNDi and Dr Joseph Gichuru, Deputy Executive Director and the Director of Operations, APHRC, alongside representatives from both organizations.

By combining DNDi’s capacity in drug development for neglected populations with APHRC’s deep-rooted expertise in population health and policy, the two organizations aim to set the stage for a more equitable ‘New Public Health Order’ in Africa.

‘This partnership is a powerful opportunity for both organizations to drive innovative solutions in research, capacity enhancement, data sharing for impact, and fundraising aimed at strengthening the R&D ecosystem,’ said DNDi’s Prof. Samuel Kariuki. 

The MoU also focuses on promoting communication and knowledge management opportunities between DNDi and APHRC,, as well as policy engagement. By pooling their institutional weight, both organizations aim to jointly secure resources for capacity-strengthening necessary to fuel long-term innovation. The partnership prioritizes the people behind the science and those it aims to serve.

‘It is evident there are avenues of collaboration especially in the shared countries of operation and thematic areas. Crucially, this partnership acknowledges the escalating climate crisis as a primary driver of future health instability,’ said APHRC’s Dr Joseph Gichuru.

Data is the ‘new oil’ of the medical world, but it must be handled with care. The MoU outlines both parties’ collaborative commitments to ethical, value-enhancing data-sharing activities, including:

  • Statistical management for pan-African studies;
  • Generation of high-quality evidence to inform population health; and
  • Creation of a robust knowledge management system to preserve and share findings.

The future of African public health must be collaborative, data-driven, and, above all, people-centred. By uniting their missions, DNDi and APHRC aim to strengthen not only their own organizations, but the health ecosystem at large.

Photo credit: Stephen Wainaina, APHRC

Partnership Africa

Read, watch, share

Loading...
News
16 Dec 2025

DNDi 2025 in Review

News
8 Dec 2025

DNDi statement on COP30: Advancing health in the climate agenda

News
4 Dec 2025

Dr Javid Abdelmoneim, Datuk Dr Mahathar bin Abd Wahab, Dr Taruna Madan, Violet Naanyu, and Dr Mario Santos Moreira join the Board of Directors at DNDi

Press releases
27 Nov 2025

International seminar explores the development of treatments for dengue for populations not covered by vaccines

News
26 Nov 2025

DNDi statement on the approval of the Instituto Butantan’s dengue vaccine and the need for a dengue treatment

Dr Pauline Williams
Videos
24 Nov 2025

Interview with Dr Pauline Williams, new DNDi Scientific Advisory Committee (SAC) Chair

Financial Times logo
Viewpoints
20 Nov 2025

Neglecting infectious diseases is a market failure

Financial Times
Videos
20 Nov 2025

Beni: Surviving Sleeping Sickness

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license